Diabetes news - the latest biotech news from Labiotech.eu

Home Diabetes Page 3

Latest Posts

Sernova

News and Trends 20 Dec 2022

Watch: Sernova’s Cell Pouch System tackles diabetes

Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System. This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

NLS Days Malmo 2022

News and Trends 20 Dec 2022

Watch: Sigrid CEO talks about lifestyle diseases

Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented. The company’s research dates back to 2008 when Bengtsson and his research group at the Department of Molecular Biosciences at Stockholm University in Sweden made discoveries […]

December 20, 2022 - 1 minutemin - By Jim Cornall

diabetes

News and Trends 16 Dec 2022

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

insulin pen diabetes

News and Trends 7 Dec 2022

FDA clears insulin pen medical device

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

skin patch diabetes

News and Trends 23 Nov 2022

Funding to develop wearable patch for type 2 diabetes

A project to develop a patch worn on the cheek that delivers peptide treatments for type 2 diabetes has been awarded just under €3.8 million ($3.9 million) by the EU’s Horizon Europe RESILIENCE program. The ‘BUCCAL-PEP’ project will combine skills to develop a multifunctional biomaterial patch which allows, for the first time, delivery of peptide […]

November 23, 2022 - 4 minutesmins - By Jim Cornall

insulin

News and Trends 22 Nov 2022

Arecor to start second type 2 diabetes clinical trial

Arecor Therapeutics plc says the BASG (Bundesamt für Sicherheit im Gesundheitswesen) has cleared the company’s clinical trial application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in type 2 diabetic patients. The CTA approval means Arecor can start its second phase I clinical trial for AT278. AT278 has previously demonstrated a faster […]

November 22, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

Ilya Pharma enrols first patient in diabetic foot ulcer study

More News! 15 Nov 2022

Destiny Pharma’s XF-73 dermal infection project advances to safety study

The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […]

November 15, 2022 - 2 minutesmins - By Liza Laws

diabetes

News and Trends 10 Nov 2022

Promising drug candidate discovered for prevention of type 1 diabetes

According to a new study in Finland, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. A drug based on the same mechanism has already been approved for the treatment of another autoimmune disease, psoriasis, in the U.S., which may boost the development of drug therapies for […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

retinal eye disease

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

insulin diabetes

News and Trends 4 Nov 2022

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA). This will enable the company to start initiating a clinical trial for type 1 diabetes using AlloStem. The primary objective of the study is to evaluate Allostem in patients with […]

November 4, 2022 - 3 minutesmins - By Liza Laws

Biocomposites Ltd shutterstock diabetic foot ulcer

News and Trends 3 Nov 2022

New method to treat diabetic foot ulcers revealed by Biocomposites Ltd

Diabetic foot infection costs the UK’s NHS around £900 million ($990 million) a year, bringing severe misery to patients. Usually, systemic antibiotics are routinely given to those with diabetes who are susceptible to infected foot ulcers. Unfortunately, effective treatment can be disrupted by complications by using this treatment due to allergic reactions, antibiotic-resistant organisms, the […]

November 3, 2022 - 3 minutesmins - By Liza Laws

diabetes hypoglycemia

News and Trends 1 Nov 2022

Tetris Pharma launches hypoglycemia injector pen in Germany

Tetris Pharma Ltd, a subsidiary of biopharma company Arecor Therapeutics plc, has launched Ogluo (glucagon prefilled autoinjector pen) in Germany as a treatment for severe hypoglycemia in children and adults living with diabetes. Ogluo is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycemia. […]

November 1, 2022 - 2 minutesmins - By Jim Cornall

ADVERTISEMENT